0 and older, any sex, with Pain, Chronic. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Patient Global Impression of Change (PGIC)Primary· 12-months post-procedure
Using the Patient Global Impression of Change (PGIC) Scale, subjects will rate themselves as: very much improved; much improved; minimally improved; no change; minimally worse; much worse; or very much worse compared with Baseline
Group
Value
95% CI
Boston Scientific Radiofrequency Ablation Systems
66
Boston Scientific Radiofrequency Ablation Systems
78
Boston Scientific Radiofrequency Ablation Systems
54
Boston Scientific Radiofrequency Ablation Systems
13
Responder RateSecondary· 12-months post-procedure
Percentage of subjects with a 30 percent or greater reduction from Baseline in targeted pain intensity
Group
Value
95% CI
Boston Scientific Radiofrequency Ablation Systems
135
Adverse events — posted to ClinicalTrials.gov
Time frame: From the time a subject signs the study Informed Consent through study completion or study withdrawal (up to 24 months)..
Reporting threshold: 1%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
The objective of this study is to compile real-world outcomes of Boston Scientific commercially approved radiofrequency (RF) ablation systems in the treatment of patients diagnosed with pain
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
NCT06732388 — Itraconazole in Combination With Ablation for the Prevention of Esophageal Cancer in Patients With High-risk Barrett's E
· Phase 2
· not yet recruiting
NCT06791629 — Pulsed Field Ablation Versus Radiofrequency Ablation for Persistent Atrial Fibrillation
· NA
· not yet recruiting
NCT05473663 — Radiofrequency Ablation After Total Knee Arthroplasty
· NA
· active not recruiting
NCT05003856 — Radiofrequency Ablation for the Treatment of Benign or Low Risk Thyroid Nodule
· NA
· terminated
NCT05433701 — Stereotactic Body Radiotherapy Versus Radiofrequency Ablation for Unresectable, Small (≤ 3 cm) HCC
· NA
· active not recruiting
NCT06512727 — The PROACTIVE Study for Black Elders
· NA
· recruiting
NCT06837857 — Prescription Opioids, Brain Structure, and Cognition in Older Adults With Chronic Pain
· Phase 2
· recruiting
NCT06541184 — Ziconotide for Non-cancer Pain by Intrathecal Administration
· recruiting
NCT06592053 — Affecting Factors for Chronic Pain After Mastectomy
· recruiting
Other Boston Scientific Corporation trials
Trials by the same sponsor.
NCT07458243 — Registry of ENROUTE NPS in Conjunction With Carotid WALLSTENT
· not yet recruiting
NCT07458217 — Combined CM and STN Stimulation for Motor Epilepsy
· NA
· not yet recruiting
NCT07276815 — OverStitch NXT Endoscopic Suture System
· NA
· not yet recruiting
NCT07353710 — A Study on the Acquisition of 2D ICE Images With the CHORUS IDx System in Subjects Undergoing an Ablation Procedure
· NA
· not yet recruiting
NCT07195708 — Orbera365 Intragastric Balloon System (Abbreviated as'Orbera365')
· NA
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Boston Scientific Corporation
Last refreshed: 15 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04673032.